Mentari Therapeutics, Inc., formerly InMed Pharmaceuticals Inc., filed a Form 8-K on November 5, 2026, disclosing a corporate name change, a 1-for-10 common share consolidation, and the creation of a new Series A Non-Voting Preferred Share class, all effective November 4, 2026, in connection with a pending merger transaction.

Key Highlights

  • Name change effective: The company legally changed its name from "InMed Pharmaceuticals Inc." to "Mentari Therapeutics, Inc." effective November 4, 2026, by filing a notice of alteration with the Province of British Columbia Registrar of Companies.
  • 1-for-10 share consolidation: Every ten Common Shares issued and outstanding were automatically consolidated into one Common Share, with no change in shareholders' proportionate equity or voting interests, effective November 4, 2026.
  • Post-consolidation trading: Common Shares are expected to begin trading on a post-consolidation basis on The Nasdaq Capital Market under the existing symbol "INM" at the commencement of trading on November 5, 2026, with a new CUSIP number of 457637809 and a new ISIN number of CA4576378091.
  • New preferred share class: 4,013 authorized but undesignated preferred shares were designated as Series A Non-Voting Preferred Shares, effective November 4, 2026, each convertible into 1,000 Common Shares at the holder's option.
  • Shareholder meeting held: The annual general and special meeting of shareholders was held on November 4, 2026, with 5,493,735 Common Shares outstanding and entitled to vote as of the September 25, 2026 record date, and 3,630,088 Common Shares represented.
  • Merger structure disclosed: The filing describes a planned merger with Mentari Therapeutics, Inc., a Delaware corporation, involving two merger subsidiaries, to be followed by a redomestication of the company from British Columbia, Canada to the State of Nevada.

Mentari Therapeutics Name Change, Share Consolidation, and Preferred Share Designation Details

According to the filing, the company formerly known as InMed Pharmaceuticals Inc. officially changed its corporate name to "Mentari Therapeutics, Inc." on November 4, 2026, by filing a notice of alteration with the Province of British Columbia Registrar of Companies. The Board of Directors had approved the name change and the share consolidation on October 23, 2026, without a separate vote of shareholders, as permitted under the company's notice of articles and articles. The amended articles reflecting the name change also became effective on November 4, 2026.

The 1-for-10 consolidation means that every ten Common Shares issued and outstanding immediately prior to the consolidation were automatically converted into one Common Share. The filing states that fractional shares resulting from the consolidation were rounded up to the nearest whole number if 0.5 or greater, and down if less than 0.5, with no cash or other consideration paid for rounding. The filing also notes that proportionate adjustments were made to the per share exercise price and number of shares issuable under all outstanding stock options and warrants, and that the number of shares reserved under the company's equity incentive plan was reduced proportionately. The Common Shares are expected to trade under the existing NASDAQ:INM symbol beginning November 5, 2026, on a post-consolidation basis.

The filing further discloses that 4,013 preferred shares were designated as Series A Non-Voting Preferred Shares. Each Series A Preferred Share is convertible into 1,000 Common Shares at the holder's option, subject to a cap initially prohibiting conversion that would result in a holder and its affiliates beneficially owning more than 19.99% of then-outstanding Common Shares. Holders of Series A Preferred Shares, voting as a separate class on an as-converted basis, retain the right to elect two directors to the Board for so long as at least 30% of the originally issued Series A Preferred Shares remain outstanding. The filing also notes that, without affirmative vote of a majority of outstanding Series A Preferred Shares, the company may not take certain actions, including altering Series A Preferred Share rights, amending the articles in a manner adverse to holders, or consummating certain change-of-control transactions.

What Was Disclosed

The filing disclosed a corporate name change from InMed Pharmaceuticals Inc. to Mentari Therapeutics, Inc., a 1-for-10 common share consolidation, the designation of 4,013 Series A Non-Voting Preferred Shares, and details of the November 4, 2026 shareholder meeting, all in connection with a pending merger and redomestication.